JPH0314516A - Structure containing percutaneous absorption drug impregnated therein - Google Patents
Structure containing percutaneous absorption drug impregnated thereinInfo
- Publication number
- JPH0314516A JPH0314516A JP14773589A JP14773589A JPH0314516A JP H0314516 A JPH0314516 A JP H0314516A JP 14773589 A JP14773589 A JP 14773589A JP 14773589 A JP14773589 A JP 14773589A JP H0314516 A JPH0314516 A JP H0314516A
- Authority
- JP
- Japan
- Prior art keywords
- adhesive tape
- drug
- impregnated
- transdermal drug
- adhesive
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 50
- 229940079593 drug Drugs 0.000 title claims abstract description 50
- 238000010521 absorption reaction Methods 0.000 title abstract description 5
- 239000002390 adhesive tape Substances 0.000 claims abstract description 35
- 239000002184 metal Substances 0.000 claims abstract description 17
- 229910052751 metal Inorganic materials 0.000 claims abstract description 15
- 239000000843 powder Substances 0.000 claims abstract description 15
- 239000012790 adhesive layer Substances 0.000 claims abstract description 13
- 229910045601 alloy Inorganic materials 0.000 claims abstract description 9
- 239000000956 alloy Substances 0.000 claims abstract description 9
- 239000000463 material Substances 0.000 claims abstract description 9
- 230000003110 anti-inflammatory effect Effects 0.000 claims abstract description 4
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical group [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 claims description 4
- 239000010936 titanium Substances 0.000 claims description 4
- 229910052719 titanium Inorganic materials 0.000 claims description 4
- 229910001069 Ti alloy Inorganic materials 0.000 claims description 3
- 230000000202 analgesic effect Effects 0.000 claims 1
- 239000000758 substrate Substances 0.000 abstract description 8
- 208000010201 Exanthema Diseases 0.000 abstract description 3
- 201000005884 exanthem Diseases 0.000 abstract description 3
- 206010037844 rash Diseases 0.000 abstract description 3
- 239000002371 cardiac agent Substances 0.000 abstract description 2
- 239000000730 antalgic agent Substances 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 230000002035 prolonged effect Effects 0.000 abstract 1
- 239000000853 adhesive Substances 0.000 description 18
- 230000001070 adhesive effect Effects 0.000 description 18
- 238000000034 method Methods 0.000 description 7
- 239000011148 porous material Substances 0.000 description 5
- 239000002344 surface layer Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 4
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 4
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 238000004891 communication Methods 0.000 description 3
- 238000005470 impregnation Methods 0.000 description 3
- -1 nitrite compound Chemical class 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 2
- LVYLCBNXHHHPSB-UHFFFAOYSA-N 2-hydroxyethyl salicylate Chemical compound OCCOC(=O)C1=CC=CC=C1O LVYLCBNXHHHPSB-UHFFFAOYSA-N 0.000 description 2
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 2
- 239000005844 Thymol Substances 0.000 description 2
- YWXYYJSYQOXTPL-JGWLITMVSA-N [(3r,3ar,6s,6as)-3-hydroxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl] nitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-JGWLITMVSA-N 0.000 description 2
- 230000037374 absorbed through the skin Effects 0.000 description 2
- 229960000846 camphor Drugs 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000005923 long-lasting effect Effects 0.000 description 2
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 2
- 229910001092 metal group alloy Inorganic materials 0.000 description 2
- 229960001047 methyl salicylate Drugs 0.000 description 2
- 235000019477 peppermint oil Nutrition 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 229960000790 thymol Drugs 0.000 description 2
- 206010003225 Arteriospasm coronary Diseases 0.000 description 1
- 208000003890 Coronary Vasospasm Diseases 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- KLDXJTOLSGUMSJ-JGWLITMVSA-N Isosorbide Chemical compound O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 KLDXJTOLSGUMSJ-JGWLITMVSA-N 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 201000011634 coronary artery vasospasm Diseases 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 229960002479 isosorbide Drugs 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000000088 plastic resin Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 238000005245 sintering Methods 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 239000000057 synthetic resin Substances 0.000 description 1
- 229920003002 synthetic resin Polymers 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
Description
【発明の詳細な説明】
産業上の利用分野
本発明は経皮吸収型薬剤含浸構造体に係り、詳しくは、
経皮吸収型薬剤等を含浸した多孔性焼結金属を基材とし
て用い、この基材を接着性テープに接着すると共に、こ
の接着性テープに非接着性テープを接合して一体化し、
使用時には非接着性のテープを剥離し、患部に貼着する
ことにより薬剤の接続性の向上ならびにタイムリーに薬
効を発Ｈさせることができ、更に、カブレが少なく、冶
掠時の看護人の手間が省略できる等の利点を有する経皮
吸収型薬剤含浸構造体に係る。DETAILED DESCRIPTION OF THE INVENTION Field of Industrial Application The present invention relates to a transdermal drug-impregnated structure, in particular:
A porous sintered metal impregnated with a transdermal drug, etc. is used as a base material, and this base material is adhered to an adhesive tape, and a non-adhesive tape is joined to the adhesive tape to integrate it.
By peeling off the non-adhesive tape and pasting it on the affected area during use, it is possible to improve the connectivity of the drug and timely effect of the drug.Furthermore, there is less rash and it is easier for nurses to administer the drug. The present invention relates to a transdermal drug-impregnated structure that has advantages such as saving time and effort.
なお、以下において経皮吸収型薬剤（以下、経皮薬剤と
いう。）とは通常使用ざれている皮膚から吸収される薬
剤はすべて含まれ、例えば、心賛薬、？Ｉ４炎ｓｔｌ＃
ｉＷ薬等が含まれる。In addition, in the following, transdermal drugs (hereinafter referred to as transdermal drugs) include all commonly used drugs that are absorbed through the skin, such as Shinsan drugs, ? I4 flame stl#
This includes iW drugs, etc.
従 来 の 技 術
従来がら、心Ｈ薬として持続性の経口投与型の亜硝酸化
合物の硝酸イソソルビド（Ｉｓｏｓｏｒｂｉｄｅ Ｄｉ
ｎｉｔｒａＨ！以下ＩＳＤＮと略記）が用いられている
が、このＩＳＤＮを経口投与すると肝臓での代謝が関与
し、効果が半減するため、近年経口投与に代って、経皮
的に吸収させるテーブの表面にＩｓＤＮを粘着剤と共に
塗布した経皮薬剤テープが市販されるようになった。こ
のテープは１度患部に貼着すると、ＩＳＤＮは徐々に皮
膚から吸収され、ＩＳＤＮの血液濃度をかなり長時間維
持でき、心筋の酸素′１４費檄を抑制する他、冠状動脈
の痙翠等を予防するという利点がある。しかし、このテ
ープを患部に貼看した場合、経口投与の場合に比べて著
しく低いが、ＩＳＵＮの血中濃度は約６時間程度でピー
クに遅し、それからだんだん減少して行き２４時間を経
過するとピークの半分程度に低下する。また、このテー
プは粘着剤で貼着するため、貼看部分の皮膚が赤くかぶ
れてしまうという問題がある。Conventional technology Traditionally, isosorbide nitrate (Isosorbide Di), a long-acting orally administered nitrite compound, has been used as a cardiac drug.
nitraH! ISDN (hereinafter abbreviated as ISDN) is used, but when ISDN is administered orally, it is metabolized in the liver and its effectiveness is halved. Transdermal drug tapes coated with IsDN along with adhesives have become commercially available. Once this tape is applied to the affected area, ISDN is gradually absorbed through the skin, maintaining the blood concentration of ISDN for a considerable period of time, suppressing myocardial oxygen demand, and preventing coronary artery spasm. It has the advantage of prevention. However, when this tape is applied to the affected area, the blood concentration of ISUN reaches its peak in about 6 hours, although it is significantly lower than when administered orally, and then gradually decreases, reaching its peak after 24 hours. It will drop to about half of that. Furthermore, since this tape is attached using an adhesive, there is a problem in that the skin where the tape is attached becomes red and irritated.
また、サリチル酸メチル、ｌ−メントール、ｄｊ−カン
フル、チモール、ハッカ油、サリチル酸モノグリコール
エステル等を配合した粘着剤を塗布した消炎ｓｌ痛用の
経皮薬剤テープが市販されているが、心臓冶僚用の経皮
薬剤テープと同様の問題がある。In addition, there are commercially available transdermal drug tapes for anti-inflammatory and SL pain coated with adhesives containing methyl salicylate, l-menthol, dj-camphor, thymol, peppermint oil, salicylic acid monoglycol ester, etc. There are similar problems with transdermal drug tapes.
すなわち、従来例の経皮薬剤テープは、経皮薬剤と粘着
剤とを適当な割合で配合した混合物がテープ等に塗布し
たものから成っているため、経皮薬剤が直接皮膚に接触
し吸収ざれる割合が小さく、その性能が十分発揮できず
、また、粘着剤がテープ全面に塗布され、直接皮膚と接
触し、汗や脂肪等の逸散ができず赤くか・ｙれ、その使
用に一定の限度が存在した。In other words, conventional transdermal drug tapes are made by applying a mixture of transdermal drugs and adhesives in appropriate proportions onto the tape, so that the transdermal drugs come into direct contact with the skin and are not absorbed. In addition, the adhesive is applied to the entire surface of the tape, and it comes into direct contact with the skin, making it impossible for sweat and fat to dissipate, resulting in redness and itching. There were limits.
発明が解次しようとする課題
本発明は上記問題の解決を目的とし、具体的には、従来
例の経皮薬剤テープでは経皮薬剤であっても直接皮膚と
接触し吸収ざれる割合や粘着剤の塗布方法等を変えるこ
とがむづかしく、また、経皮薬剤の性能が十分に発揮で
きず、タイムリーな薬効や￥ｆ続性等に劣る他、貼看に
よるか・ｙれ現象が皮膚面に生ずる等の問題を解決した
経皮吸収型薬剤含浸構造体を提案するものである。Problems to be Solved by the Invention The purpose of the present invention is to solve the above-mentioned problems.Specifically, in conventional transdermal drug tapes, even if transdermal drugs come into direct contact with the skin, the rate at which they are absorbed and the adhesiveness It is difficult to change the method of applying the drug, and the performance of transdermal drugs cannot be fully demonstrated, and the timely efficacy and persistence of the drug are poor. This paper proposes a transdermal absorption type drug-impregnated structure that solves problems such as those occurring on the skin surface.
課題を解決するための
手段ならびにその作用
すなわち、本発明は、経皮吸収型薬剤が含浸されて、し
かも、金属若しくは合金粉末が焼結された多孔性焼結金
属からなる基材を一方の面が粘着剤層である粘着性テー
プの粘着剤層に接着すると共に、この接着性テープに非
接着性テブを接着して一体化してなることを￥１黴とす
る。Means for Solving the Problems and Their Effects Namely, the present invention provides a substrate made of porous sintered metal impregnated with a transdermal drug and sintered with metal or alloy powder on one side. is adhered to the adhesive layer of an adhesive tape, which is an adhesive layer, and a non-adhesive tape is adhered to and integrated with this adhesive tape for 1 yen.
そこで、これらの手段たる構成ならびにその作用につい
て更に具体的に説明すると、次の通りである。Therefore, the structure of these means and their operation will be explained in more detail as follows.
まず、本発明者等は経皮薬剤テープが経皮薬剤のもつ性
能が十分発揮できず、また、薬効の持続性に劣る等の理
由について検討したところ、経皮薬剤と粘着剤とを混合
すると、経皮薬剤の一部が粘着剤中に封じ込められるた
めであることが判った。First, the present inventors investigated the reasons why transdermal drug tapes do not fully demonstrate the performance of transdermal drugs and have inferior long-lasting drug efficacy, and found that when a transdermal drug and an adhesive are mixed together, It was found that this is because a portion of the transdermal drug is encapsulated in the adhesive.
しかし、経皮薬剤と粘着剤とを混合しないと、患部の皮
膚にｌｌ１続して経皮薬剤を接触させることがむづかし
いことから更に検討を行なったところ、金属や合金粉末
の多孔性焼結体に経皮薬剤を含浸させ、この含浸焼結体
を粘着性テープで患部等の皮膚に接着すればよいという
知見を得た。However, unless the transdermal drug and adhesive are mixed together, it is difficult to bring the transdermal drug into continuous contact with the affected skin.After further investigation, we found that a porous sintered body of metal or alloy powder It has been found that the impregnated sintered body can be impregnated with a transdermal drug and the impregnated sintered body can be adhered to the skin of the affected area using adhesive tape.
更に進んで研究を行ない、この研究に基づいて本発明は
或立したものである。Further research was conducted, and the present invention was established based on this research.
以下、図面に従って本発明を詳しく説明する。Hereinafter, the present invention will be explained in detail with reference to the drawings.
第１図は本発明に係る一つの実施例の経皮薬剤含浸構造
体の断面図であり、第２図（ａ）ならびに（ｂ）はそれ
ぞれ第１図の基体の斜視図ならびにＡ−Ａ線断面図であ
り、第３図は第１図の経皮薬剤含浸構造体の使用状況の
説明図である。FIG. 1 is a sectional view of a transdermal drug-impregnated structure according to one embodiment of the present invention, and FIGS. 2(a) and 2(b) are a perspective view of the base body in FIG. 1 and a line A-A, respectively. 3 is a sectional view, and FIG. 3 is an explanatory diagram of the usage situation of the transdermal drug-impregnated structure of FIG. 1.
符号１は経皮薬剤含浸構造体、２は粘着性テープ、３は
粘着剤層、４は基体、４ａは表層部、４ｂは裏面図、５
は非粘着性テープ、６は皮膚面を示す。1 is a transdermal drug-impregnated structure, 2 is an adhesive tape, 3 is an adhesive layer, 4 is a substrate, 4a is a surface layer portion, 4b is a back view, 5
6 indicates the non-adhesive tape, and 6 indicates the skin surface.
第１図に示す経皮薬剤含浸構造体１は一方の面に粘着剤
１ｉ１３を具えた例えば円形状の粘着性テーブ２とこの
粘肴剤層３の中心部に経皮薬剤を含浸した多孔質焼結金
属がらなる基体４と、この基体４を上方から囲むよう非
粘着性テーブ５を配置し、粘着性テープ２と接合し一体
化した構造のものから構成ざれ、第３図に示すように非
粘着性テーブ５を剥離すると患部の皮膚面６に貼看でき
るように構成したものから成る。The transdermal drug-impregnated structure 1 shown in FIG. 1 includes, for example, a circular adhesive tape 2 provided with an adhesive 1i13 on one side, and a porous structure impregnated with a transdermal drug in the center of this adhesive layer 3. It consists of a base body 4 made of sintered metal, a non-adhesive tape 5 arranged so as to surround the base body 4 from above, and joined to an adhesive tape 2 to form an integrated structure, as shown in Fig. 3. The non-adhesive tape 5 is constructed so that it can be applied to the skin surface 6 of the affected area when peeled off.
なお、基体４は金属若しくは合金粉末を主成分とする金
属粉末を成形ならびに焼結し、例えば、孔隙率２０％以
上の孔隙を有するものから戒って、これら孔隙に経皮薬
剤を含浸させたものから戊る。The base body 4 is made by molding and sintering metal powder whose main component is metal or alloy powder, and for example, avoids having pores with a porosity of 20% or more, and impregnating these pores with a transdermal drug. Get rid of things.
なお、金属若しくは合金粉末としては、皮膚に悪影響を
与えないもので経皮薬剤に溶解若しくは反応しないもの
であればよく、例えば、金属チタン、チタン合金があげ
られる。The metal or alloy powder may be any powder that does not adversely affect the skin and does not dissolve or react with transdermal drugs, such as titanium metal and titanium alloys.
更に、基体４の表面には第２図（ａ）ならびに（Ｉｌ）
に示すように表層部４ａを形成し、表＠８ＩＳ４ａを内
部に比べて孔隙率が小さく密度を大きくし研磨すると、
表面１ｔｆなめらかで光沢を持つようになる。この際、
表園部４ａはいずれの方法によつて形成しても良いが、
通常は粉末粒子を殆んど加圧することなく、例えば、円
盤状形状に成形してから焼結し、その後、更に表面のみ
を加圧して表層部４ａを形戒するものが好ましい。この
ようにＷ４Ｉｉｌ２すると、内部は各粉末粒子間の屈折
する孔隙若しくは連通孔が形成ざれるのに対し、表層部
４ａでは孔隙や連通孔の径が内部に較べて極端に小さく
なる。Further, on the surface of the base 4, there are shown in FIGS. 2(a) and (Il).
When the surface layer 4a is formed as shown in , and the surface layer 4a is polished to have a smaller porosity and a higher density than the inside,
The surface becomes 1tf smooth and glossy. On this occasion,
The front garden part 4a may be formed by any method, but
Usually, it is preferable to form the powder particles into a disc-like shape and sinter it without applying much pressure to the powder particles, and then further pressurize only the surface to shape the surface layer 4a. When W4Iil2 is performed in this manner, bending pores or communication holes between the powder particles are not formed in the inside, whereas the diameters of the pores and communication holes in the surface layer portion 4a are extremely smaller than those in the inside.
従って、多孔質焼結体からなる基体４の裏面部４ｂに露
出する孔隙若しくは連通孔から経皮薬剤を例えば真空含
浸法により含浸させると、表商部４ａからの経皮薬剤の
発敗が極めて緩慢であるため、長時間にわたって薬効が
発揮する。このようにして形成した基体４の裏面部４ｂ
を粘着性テーブ２の粘着剤囮３に接合し接＠するように
構或する。Therefore, when a transdermal drug is impregnated through the pores or communication holes exposed in the back surface portion 4b of the base body 4 made of a porous sintered body by, for example, a vacuum impregnation method, the transdermal drug from the front surface portion 4a is extremely unlikely to be lost. Because it is slow-acting, it exerts its medicinal effects over a long period of time. Back surface portion 4b of base body 4 formed in this way
is connected to and in contact with the adhesive decoy 3 of the adhesive tape 2.
また、基体４の形状は例えば円盤状で、直径５〜１０１
１１１１１、高さ１〜５ｍｌＩ１程度のものが貼者なら
びに取扱いに便利で好ましい。塞体４のＭｓ戊材料とし
ては金属若しくは合金粉末で皮膚に障害を与えないもの
で、しがも、経皮薬剤に溶解若しくは反応しないもので
あればよく、例えば、金属チタンやチタン合金があげら
れる。粘着性テブは基体４を思部の皮膚面６に貼看し、
固定できるものであればよく、基体４の直径に対し、１
．５〜２．５倍程度の直径のものであれば十分である。Further, the shape of the base body 4 is, for example, a disk shape, with a diameter of 5 to 101 mm.
11111 and a height of about 1 to 5 mlI1 is preferred because it is convenient for the person applying the adhesive and for handling. The material for the plug 4 may be metal or alloy powder that does not harm the skin and does not dissolve or react with transdermal drugs, such as titanium metal or titanium alloys. It will be done. Adhesive tape adheres the base 4 to the skin surface 6 of the buttocks,
Any material that can be fixed may be used, and the diameter of the base 4 should be 1
．． A diameter of about 5 to 2.5 times is sufficient.
非粘着性テープは粘着性テープの粘着剤層を被覆する程
度のものであればよく、基体４の表面を被覆若しくは被
覆しない形状のものであってもよい。The non-adhesive tape may be of a shape that covers the adhesive layer of the adhesive tape, and may be of a shape that covers or does not cover the surface of the base 4.
以上基体４を円盤状のものを中心に説明したが、基体４
を必ずしも円盤状のものに限られるものではなく、患部
の皮膚而６に傷等を与えるものでなければ十分使用でき
、これに応じて粘着性テープ形状も変えられることは明
らかである。経皮薬剤としては特に制限はなく通常経皮
薬剤として用いられるものであればよい。例えば、ニト
ログリセリン、硝酸イソソルビド等の心ｗｉ薬、サリチ
ル酸メチル、ｌ−メントール、ｄｉ一カンフル、チモー
ル、ハッカ油、サリチル酸モノグリコールエステル、酢
酸トコフエロル等を混合したものからなる消炎鎮痛朶等
があげられるが、これらに限られるものではない。Although the base 4 has been mainly explained in the form of a disk, the base 4
It is clear that the adhesive tape is not necessarily limited to a disk shape, and can be used as long as it does not cause damage to the skin 6 of the affected area, and the shape of the adhesive tape can be changed accordingly. There are no particular limitations on the transdermal drug, as long as it is commonly used as a transdermal drug. Examples include anti-inflammatory and analgesic soaps made of a mixture of stimulants such as nitroglycerin and isosorbide nitrate, methyl salicylate, l-menthol, di-camphor, thymol, peppermint oil, monoglycol salicylate, and tocopherol acetate. However, it is not limited to these.
これらの多孔質焼結体に含浸させる方法としては、通常
知られている方法、例えば、頁空含浸法等が適用できる
。この場合、液体として用いることが好ましく、適当な
溶剤等に溶解して含浸させればよい。As a method for impregnating these porous sintered bodies, commonly known methods such as page void impregnation method can be applied. In this case, it is preferable to use it as a liquid, and it may be dissolved in a suitable solvent or the like and impregnated.
実施例 以下、実施例について説明する。Example Examples will be described below.
実施例１．
直径５ｌＩｌｆｆｌ、高さ２術の円盤状多孔買金属チタ
ン焼結体にＩＳＤＮを真空含浸法により含浸させて基体
を作或した。この基体を直径２０ｍｍの一万の面に粘着
剤を塗布した合成樹脂粘着テープに接続し、この粘着剤
層を非粘着性紙テープにより接合して一体化した。Example 1. A substrate was prepared by impregnating ISDN into a disc-shaped porous titanium sintered body having a diameter of 5 liters and a height of 2 mm by a vacuum impregnation method. This substrate was connected to a synthetic resin adhesive tape having 10,000 sides coated with an adhesive and having a diameter of 20 mm, and the adhesive layer was joined with a non-adhesive paper tape to form an integrated structure.
これをアルミニウム箔袋に挿入して製品とした。この製
品を開利して非粘管性テープを制離し虚血性心疾患者の
胸部に貼看しＩＳＤＮ血中濃度を調べたところ、粘着後
直ちに高い濃度となり、３日後も同様のＩＳＤＮ血中濃
度であった。This was inserted into an aluminum foil bag to produce a product. When this product was used to release a non-viscous tape and applied it to the chest of a patient with ischemic heart disease, the blood concentration of ISDN was examined. It was the concentration.
実施例２．
非粘着性紙テープの代りに粘着剤を塗布しないテフロン
系樹脂フィルムで基材を被覆し一体化した以外は実施例
１と同様に行なった結果、実施例１と同様な効果が得ら
れた。Example 2. Example 1 was carried out in the same manner as in Example 1, except that the base material was coated and integrated with a Teflon resin film without adhesive instead of the non-adhesive paper tape, and the same effects as in Example 1 were obtained.
実施例３．
経皮薬剤をサリチル酸メチル、ｌ−メントル、ｄｉ一カ
ンフル、チモール、ハッカ油、サリチル酸モノグリコー
ルエステルをそれぞれ１２．５ｇ， １１．８（１、２
．０（１、１．５ｇ、０．５ｇ、３．４０の割合で混合
した混合物を用いた以外は実施例１と同様に製品を製造
し、合戊樹脂袋に到入して製品とした。Example 3. For transdermal drugs, 12.5 g and 11.8 g (1, 2
．． A product was manufactured in the same manner as in Example 1 except that a mixture of 0(1, 1.5 g, 0.5 g, and 3.40) was used, and the product was placed in a plastic resin bag.
この製品を開封し、非粘着性テープを剥離して肩こり患
部に塗布したところ、市販品に比べて薬効が著しく大で
長時間薬効が保持され、また、かぶれ等が少ない優れた
ものであった。When I opened this product, peeled off the non-adhesive tape, and applied it to the affected area of my stiff shoulders, I found that the medicinal efficacy was significantly higher than that of commercially available products, and the medicinal efficacy was maintained for a long time, and it was superior in that it caused less irritation. .
〈発明の効果〉
以上詳しく説明したように、本発明は、経皮吸収型薬剤
が含浸されて、しかも、金属若しくは合金粉末が焼結さ
れた多孔性焼結金属がらなる基材を一方の面が粘着剤圀
である粘着性テープの粘着剤園に接着すると共に、この
接着性テープに非接看性テープを接着して一体化してな
ることを特徴とする。<Effects of the Invention> As explained in detail above, the present invention has a substrate made of porous sintered metal impregnated with a transdermal drug and sintered with metal or alloy powder on one side. is bonded to an adhesive field of an adhesive tape, and a non-contactable tape is bonded to this adhesive tape to be integrated.
従って、多孔質焼結体に経皮薬剤を含浸ざせ、これを粘
着性テープで患部の皮膚に貼着させるようにしたため、
従来例のように経皮薬剤と粘着剤とを混合して患部の皮
膚に貼着したものに比べて薬剤の速効性、持続性を有し
、粘着剤と接する割合が少ないため、かぶれ等が少なく
、取扱いが簡単であるという優れたものである。Therefore, by impregnating a porous sintered body with a transdermal drug and attaching it to the affected skin with adhesive tape,
Compared to conventional methods, which mix transdermal drugs and adhesives and apply them to the affected skin, the drugs are more effective and long-lasting, and because there is less contact with the adhesive, there is no risk of rashes, etc. It is excellent in that it is small and easy to handle.
第１図は本発明に係る一つの実施例の経皮薬剤含浸構造
体の断面図、第２図（ａ）ならびに（ｂ）はそれぞれ第
１図の基体の斜視図ならびにＡ−Ａ線断面図、第３図は
第１図の経皮薬剤含浸構造体の使用状況の説明図である
。
符号１・・・・・・経皮薬剤含浸構造体２・・・・・・
粘着性テーブ ３・・・・・・粘着剤層４・・・・・・
基体 ４ａ・・・・・・表瘤部４ｂ・・・・・
・裏面部
５・・・・・・非粘着性テープ
６・・・・・・皮膚而FIG. 1 is a sectional view of a transdermal drug-impregnated structure according to an embodiment of the present invention, and FIGS. 2(a) and 2(b) are a perspective view and a sectional view taken along the line A-A of the base shown in FIG. 1, respectively. , FIG. 3 is an explanatory diagram of the usage situation of the transdermal drug-impregnated structure of FIG. 1. Code 1... Transdermal drug-impregnated structure 2...
Adhesive tape 3...Adhesive layer 4...
Base body 4a... Surface lump part 4b...
・Back part 5...Non-adhesive tape 6...Skin area
Claims (1)
は合金粉末が焼結された多孔性焼結金属からなる基材を
一方の面が粘着剤層である粘着性テープの粘着剤層に接
着すると共に、この接着性テープに非接着性テープを接
着して一体化してなることを特徴とする経皮吸収型薬剤
含浸構造体。 ２）前記金属若しくは合金粉末がチタン若しくはチタン
合金粉末である請求項１記載の経皮吸収型薬剤含浸構造
体。 ３）前記基材が円盤状の形状でその直径が５〜１０ｍｍ
、高さが１〜５ｍｍである請求項１記載の経皮吸収型薬
剤含浸構造体。 ４）前記経皮吸収型薬剤含浸構造体が心臓薬、消炎鎮痛
薬等である請求項１記載の経皮吸収型薬剤含浸構造体。[Scope of Claims] 1) A base material made of porous sintered metal impregnated with a transdermal drug and sintered with metal or alloy powder, and having an adhesive layer on one side. What is claimed is: 1. A transdermal drug-impregnated structure, characterized in that it is bonded to an adhesive layer of a tape, and is formed by bonding and integrating a non-adhesive tape to the adhesive tape. 2) The transdermal drug-impregnated structure according to claim 1, wherein the metal or alloy powder is titanium or titanium alloy powder. 3) The base material is disc-shaped and has a diameter of 5 to 10 mm.
2. The transdermal drug-impregnated structure according to claim 1, which has a height of 1 to 5 mm. 4) The transdermal drug-impregnated structure according to claim 1, wherein the transdermal drug-impregnated structure is a heart drug, an anti-inflammatory analgesic, or the like.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP14773589A JPH0314516A (en) | 1989-06-09 | 1989-06-09 | Structure containing percutaneous absorption drug impregnated therein |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP14773589A JPH0314516A (en) | 1989-06-09 | 1989-06-09 | Structure containing percutaneous absorption drug impregnated therein |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH0314516A true JPH0314516A (en) | 1991-01-23 |
Family
ID=15436960
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP14773589A Pending JPH0314516A (en) | 1989-06-09 | 1989-06-09 | Structure containing percutaneous absorption drug impregnated therein |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH0314516A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6723120B2 (en) | 1997-04-15 | 2004-04-20 | Advanced Cardiovascular Systems, Inc. | Medicated porous metal prosthesis |
| US6805898B1 (en) | 2000-09-28 | 2004-10-19 | Advanced Cardiovascular Systems, Inc. | Surface features of an implantable medical device |
| US10028851B2 (en) | 1997-04-15 | 2018-07-24 | Advanced Cardiovascular Systems, Inc. | Coatings for controlling erosion of a substrate of an implantable medical device |
| JP2022525817A (en) * | 2019-04-02 | 2022-05-19 | ユニリーバー・アイピー・ホールディングス・ベー・フェー | Cleaning composition |
-
1989
- 1989-06-09 JP JP14773589A patent/JPH0314516A/en active Pending
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6723120B2 (en) | 1997-04-15 | 2004-04-20 | Advanced Cardiovascular Systems, Inc. | Medicated porous metal prosthesis |
| US10028851B2 (en) | 1997-04-15 | 2018-07-24 | Advanced Cardiovascular Systems, Inc. | Coatings for controlling erosion of a substrate of an implantable medical device |
| US6805898B1 (en) | 2000-09-28 | 2004-10-19 | Advanced Cardiovascular Systems, Inc. | Surface features of an implantable medical device |
| US7335314B2 (en) | 2000-09-28 | 2008-02-26 | Advanced Cardiovascular Systems Inc. | Method of making an implantable medical device |
| JP2022525817A (en) * | 2019-04-02 | 2022-05-19 | ユニリーバー・アイピー・ホールディングス・ベー・フェー | Cleaning composition |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2009233617B2 (en) | Dermal, transdermal, mucosal or transmucosal ingredient delivery devices | |
| CA2098196C (en) | Method and systems for administering drugs transdermally using sorbitan esters as skin permeation enhancers | |
| KR100267359B1 (en) | Transdermal administration system containing acetylsalicylic acid for antithrombotic therapy | |
| KR910002250B1 (en) | Plaster containing active ingredients for controlles administration of active ingredients to the skin | |
| EP0451202A1 (en) | Application system for drug containing microemulsions. | |
| JPH04506062A (en) | Device for administering active agents to the skin or mucous membranes | |
| JPS5822057A (en) | Treating system by new bandage | |
| AU2010201707A1 (en) | Topical methadone compositions and methods for using the same | |
| JPS62148421A (en) | Percutaneous patch | |
| JP2007520262A (en) | Method for treating side effects associated with transdermal or topical drug delivery | |
| US4765986A (en) | Medicinal plaster for systemic use | |
| US4788064A (en) | Transdermal delivery system | |
| JPH0314516A (en) | Structure containing percutaneous absorption drug impregnated therein | |
| JPS5925320A (en) | Plaster for drug administration | |
| JPS63203616A (en) | Clonidine percutaneous administration matrix | |
| JPS59131367A (en) | Apparatus for subcataneously administering active component | |
| DE10340428A1 (en) | Opioides analgesic containing transdermal formulation | |
| JP2781016B2 (en) | Transdermal formulation | |
| JP3295735B2 (en) | Estriol transdermal patch | |
| NZ258129A (en) | Transdermal system for applying acetylsalicylic acid or salts thereof for antithrombotic treatment or cancer proplylaxis | |
| JP3192494B2 (en) | Anti-inflammatory / analgesic for transdermal administration | |
| JPH07500114A (en) | Transdermal azidothymidine | |
| JPS6296430A (en) | Drug preparation for transcutaneous or transmucosal administration | |
| WO1999008664A1 (en) | Support for patches and patches provided with the support | |
| JPH031451Y2 (en) |